S
Stephen C. Reingold
Researcher at Salisbury University
Publications - 68
Citations - 39188
Stephen C. Reingold is an academic researcher from Salisbury University. The author has contributed to research in topics: Multiple sclerosis & Clinical trial. The author has an hindex of 37, co-authored 68 publications receiving 34843 citations. Previous affiliations of Stephen C. Reingold include National Multiple Sclerosis Society.
Papers
More filters
Journal Article
Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Authors' reply
Journal ArticleDOI
A systematic review of the incidence and prevalence of cancer in multiple sclerosis
Ruth Ann Marrie,Nadia Reider,Jeffrey A. Cohen,Olaf Stüve,Maria Trojano,Per Soelberg Sørensen,Stephen C. Reingold,Gary Cutter +7 more
TL;DR: The complexity of understanding cancer risk in MS is augmented by inconsistencies in study design, and the relative paucity of age, sex and ethnicity-specific risk estimates from which the strong impact of age on the incidence of cancers can be assessed.
Journal ArticleDOI
Pregnancy, sex and hormonal factors in multiple sclerosis
TL;DR: Recommendations are provided for counseling and management of people with MS before conception, during pregnancy and after delivery and the use of disease-modifying and symptomatic therapies in pregnancy is problematic and such treatments are normally discontinued.
Journal ArticleDOI
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruce A.C. Cree,Gary Cutter,Jerry S. Wolinsky,M. S. Freedman,Giancarlo Comi,Gavin Giovannoni,Hans-Peter Hartung,Douglas L. Arnold,Jens Kuhle,Valerie J Block,Frederick E. Munschauer,Frédéric Sedel,Fred D. Lublin,Stephen C. Reingold,Pierre Duquette,Tobias Derfuss,Franz Fazekas,Maria Pia Sormani,Robert P. Lisak,Jennifer Graves,Stephen Krieger,Rana K. Zabad,Scott D. Newsome,Joshua Barton,Richard MacDonell,Mark Marriott,Nina De Klippel,Guy Laureys,Barbara Willekens,Virginia Devonshire,Mark S. Freedman,J. Marc Girard,Paul S. Giacomini,Roger McKelvey,Daniel Selchen,Galina Vorobeychik,Ludivine Witkowski,Radek Ampapa,Jana Lizrova Preiningerova,Eva Meluzinova,R. Talab,Marta Vachova,Orhan Aktas,Mathias Buttmann,Elias Hamp Birte,Tania Kuempfel,Paul Friedemann,Daniela Rau,Gerd Reifschneider,Piotr Sokolowski,Hayrettin Tumani,Maria Satori,Carlo Pozzilli,Agata Klosek,Jozef Koscielniak,Fryze Waldemar,Malgorzata Zajda,Rafael Arroyo Gonzalez,Guillermo Izquierdo Ayuso,Victoria Fernandez Sanchez,Celia Oreja Guevara,Jose Enrique Martinez Rodriguez,Xavier Montalban,Lluís Ramió-Torrentà,Lou Brundin,Jan Lycke,Murat Terzi,Joe Guadagno,Don J. Mahad,Adrian Pace,Klaus Schmierer,Ahmed T. Toosy,Stewart Webb,Mark A. Agius,Lilyana Amezcua,Michelle L Apperson,Bridget Bagert,Daniel Bandari,Evanthia Bernitsas,Jonathan Calkwood,Jonathan Carter,Bruce A. Cohen,Devon S. Conway,Joanna Cooper,John R. Corboy,Patricia K. Coyle,Bruce C.A. Cree,Mitchel Freedman,Corey C. Ford,Edward Fox,Myla D. Goldman,Benjamin Greenberg,Mariko Kita,Thomas Leist,Sharon G. Lynch,Aaron E. Miller,Harold L. Moses,Robert T. Naismith,Mary Ann Picone,Bhatia Perminder,Alexander Rae-Grant,Kottil Rammohan,Anthony T. Reder,Claire S Riley,Derrick Robertson,Vernon Rowe,Shiv Saidha,Lawrence Samkoff,Christopher Severson,Kyle Smoot,Sharon Stoll,Randall Trudell,Bianca Weinstock-Guttman,Sanjay Yathiraj +113 more
TL;DR: This study showed that MD 1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1002 cannot be recommended for treatment of progressive multipleclerosis.
Journal ArticleDOI
Recommendations for observational studies of comorbidity in multiple sclerosis
Ruth Ann M Marrie,Aaron Miller,Maria Pia Sormani,Alan J. Thompson,Emmanuelle Waubant,Maria Trojano,Paul O'Connor,Kirsten M. Fiest,Nadia Reider,Stephen C. Reingold,Jeffrey A. Cohen +10 more
TL;DR: Recommendations will help address knowledge gaps regarding the incidence, prevalence, and effect of comorbidity on outcomes in MS and help identify MS outcomes that should be prioritized in such studies.